Shire to acquire Jerini adding Bradykinin antagonist Icatibant to portfolio « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
July 2008

M T W T F S S

« Jun Aug »

1 2 3 4 5 6

7 8 9 10 11 12 13

14 15 16 17 18 19 20

21 22 23 24 25 26 27

28 29 30 31

Shire to acquire Jerini adding Bradykinin antagonist Icatibant to portfolio

Posted on July 7, 2008 by crimsoncanary

Shire has proposed the acquisition of biotechnology company Jerini AG with which it will acquire hereditary angioedema product, Icatibant (Firazyr). Icatibant is a peptide Bradykinin B2 receptor antagonist

Filed under: gpcr | Tagged: antagonist, Bradykinin B2, gpcr, Jerini, Licensing, Shire

« Senetek terminate license agreement with Ardana for Invicorp SkyePharmas Third Flutiform Phase III Study meets endpoints »

Leave a Reply